Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Aclarion, Inc. ( (ACON) ).
On January 9, 2026, Aclarion closed a $10.4 million registered direct common-stock-only financing at $5.18 per share, a transaction the company says materially strengthens its balance sheet, preserves capital structure integrity and significantly extends its operating runway. As of January 12, 2026, Aclarion reported $21.6 million in cash, zero debt and a cash runway extended into 2028, positioning it to advance clinical validation of its Nociscan platform, accelerate enrollment in its CLARITY trial, expand MRI manufacturer access, roll out an updated Nociscan software version and deepen engagement with clinicians and U.S. commercial payers on reimbursement, thereby enhancing its strategic flexibility and growth prospects in the spine care market.
The most recent analyst rating on (ACON) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Aclarion, Inc. stock, see the ACON Stock Forecast page.
More about Aclarion, Inc.
Aclarion, Inc. is a commercial-stage healthcare technology company that leverages magnetic resonance spectroscopy, proprietary signal processing, biomarkers and augmented intelligence algorithms to optimize clinical treatments. The company is initially focused on the chronic low back pain market with Nociscan, a cloud-based, evidence-supported SaaS platform that analyzes MRI-derived MRS data to help physicians distinguish between painful and nonpainful lumbar discs, providing insights that can guide more precise treatment strategies.
Average Trading Volume: 804,246
Technical Sentiment Signal: Sell
Current Market Cap: $3.21M
For detailed information about ACON stock, go to TipRanks’ Stock Analysis page.